phrykt

Valion Bio, Inc. (VBIO): who owns it and who trades it

As of Nov 12, 2026, VBIO insiders reported 2 purchases worth $28.4K in the last 12 months. The largest buyer was Christina Rizopoulos Valauri (Director), with $18.1K.

Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, VBIO insiders reported $28.4K of open-market purchases and $0 of sales.

Purchases, 12 months
$28.4K
2 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Apr 15, 2026
Filed Apr 20, 2026

Purchases and sales by month

$28.4K$28.4KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Apr 15, 2026Sheryle BoltonDirectorPurchase10,000$1.04$10.4KForm 4
Apr 1, 2026Christina Rizopoulos ValauriDirectorPurchase19,000$0.95$18.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Christina Rizopoulos ValauriDirector$18.1K–Apr 1, 2026
Sheryle BoltonDirector$10.4K–Apr 15, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VBIO short interest

Low short interest. 1.0% of VBIO shares are sold short: about 1 share in 96. Over the last 12 reports the number of shares short went up 14%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 230,766 VBIO shares were sold short, 1.0% of the shares outstanding, up 99.8% from the report before. At the average daily volume of 1.68M shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

1.04%May 15Oct 3033.5%

Days to cover

1.0May 15Oct 302.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026230,7661.04%+100%1.68M1.0
Oct 15, 2026115,4900.52%+31%1.40M1.0
Sep 30, 202687,9680.40%+129%5.96M1.0
Sep 15, 202638,4270.17%-89%136,4921.0
Aug 31, 2026340,1861.53%-79%786,0301.0
Aug 14, 20261.65M7.42%+96%33.62M1.0
Jul 31, 2026837,86829.11%+218%1.31M1.0
Jul 15, 2026263,8909.17%+70%201,0321.3
Jun 30, 2026155,2355.39%-40%252,0501.0
Jun 15, 2026260,3609.05%+74%693,0611.0
May 29, 2026149,7955.20%-26%76,1092.0
May 15, 2026203,2777.06%-17%336,7701.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Valion Bio company events

Valion Bio filed 33 reports on Form 8-K in the last 12 months, 9 of them about an important change (leadership, listing). The latest was on Nov 9, 2026.

  1. Nov 9, 2026AgreementSeries B Closing Valion Bio, Inc., a Delaware corporation, and 3i, LP are party to that certain Securities Purchase Agreement, dated as of April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B Preferred Purchase Agreement”), with respect to the purchase and sale of (a) up to… Filing
  2. Nov 5, 2026LeadershipLisa Wolf notified the Special Committee of the Board of Directors of Valion Bio, Inc. of her decision to voluntarily resign from her positions as President, Chief Operating Officer and Chief Financial Officer of the Company. Filing
  3. Nov 2, 2026LeadershipValion Bio, Inc. notified Melinda Lackey, the Company’s General Counsel and Senior Vice President of Legal Affairs, of the termination of her employment, effective October 30, 2026. Filing
  4. Oct 29, 2026AnnouncementMade another announcement. Filing
  5. Oct 27, 2026AgreementSeries B Closing Valion Bio, Inc., a Delaware corporation, and 3i, LP are party to that certain Securities Purchase Agreement, dated as of April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B Preferred Purchase Agreement”), with respect to the purchase and sale of (a) up to… Filing
  6. Oct 26, 2026AnnouncementMade another announcement. Filing
  7. Oct 22, 2026AnnouncementMade another announcement. Filing
  8. Oct 15, 2026AnnouncementMade another announcement. Filing
  9. Oct 14, 2026AnnouncementMade another announcement. Filing
  10. Oct 8, 2026AgreementValion Bio, Inc., a Delaware corporation, and 3i, LP are parties to that certain Securities Purchase Agreement, dated as of April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B Preferred Purchase Agreement”), with respect to the purchase and sale of (a) up to 8,400 shares… Filing
  11. Oct 6, 2026AnnouncementMade another announcement. Filing
  12. Oct 1, 2026AnnouncementMade another announcement. Filing
  13. Sep 23, 2026LeadershipValion Bio, Inc., a Delaware corporation, appointed Dean Zikria as Interim Chief Executive Officer of the Company, effective immediately. Filing
  14. Sep 1, 2026LeadershipThe Company appointed Jared Malbin as a member of the board of directors, effective immediately. Filing
  15. Aug 27, 2026SharesChanged the rights of its shareholders. Filing
  16. Aug 20, 2026VoteAmended an earlier report. Reported shareholder vote results. Filing
  17. Aug 17, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
  18. Aug 6, 2026AgreementThe Company issued an aggregate of 1,287.8685 shares of Series A Preferred Stock, as consideration for the Milestone Payment (as discussed in more detail in Item 8.01 below), to Statera and Avenue Venture Opportunities Fund, L.P. Filing
  19. Jul 14, 2026AnnouncementShared information with investors. Filing
  20. Jun 18, 2026AnnouncementAs previously announced, on April 29, 2025, Valion Bio, Inc. (formerly known as Tivic Health Systems, Inc.) entered into a Securities Purchase Agreement (as subsequent assigned and amended, the “Purchase Agreement”) with an investor, pursuant to which, subject to the conditions set forth therein… Filing
  21. Jun 3, 2026LeadershipAmendment to the Company’s Amended and Restated 2021 Equity Incentive Plan As described in Item 5.07 below, on May 28, 2026, at the 2026 Annual Meeting of Stockholders of Valion Bio, Inc., the Company’s stockholders approved an amendment to the Company’s 2021 Amended and Restated 2021 Equity… Filing
  22. May 14, 2026ResultsReleased financial results. Filing
  23. May 4, 2026LeadershipMelinda Lackey was appointed as General Counsel and Senior Vice President of Legal Affairs of Valion Bio, Inc. (formerly known as Tivic Health Systems, Inc.), a Delaware corporation. Filing
  24. Apr 23, 2026RulesChanged its bylaws or articles. Filing
  25. Mar 25, 2026ResultsReleased financial results. Filing
  26. Mar 20, 2026ListingTivic Health Systems, Inc. received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because the closing bid price for the Company’s common stock was below $1.00 per share for at least 30 consecutive business days… Filing
  27. Mar 13, 2026AgreementTivic Health Systems, Inc.’s wholly owned subsidiary Velocity Bioworks, Inc. entered into a Building Lease Agreement with TPB Merchants Ice LLC to lease an approximately 8,024 square foot facility located at 1305 E. Houston St., San Antonio, TX 78205. Filing
  28. Mar 11, 2026AnnouncementThe Board of Directors of the Company adopted a resolution, pursuant to Section 2.16 of the Bylaws, to cancel the Adjourned Meeting. Filing
  29. Mar 4, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
  30. Feb 9, 2026AgreementTivic Health Systems, Inc. entered into a Common Stock Purchase Agreement with Tumim Stone Capital, LLC, a Delaware limited liability company. Filing
  31. Jan 20, 2026AnnouncementShared information with investors. Filing
  32. Dec 11, 2025DealThe information contained above in Item 1.01 regarding VBI’s purchase of the Acquired Assets pursuant to the APA and the Bill of Sale is hereby incorporated by reference into this Item 2.01. Filing
  33. Nov 18, 2025AnnouncementMade another announcement. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Valion Bio financials

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named VBIO in the last 120 days.

FiledHolderFormStake
Nov 12, 20263i, LP13G/A9.9%
Nov 12, 20263i, LP13G/A9.9%

Questions about Valion Bio, Inc. (VBIO) stock

Are VBIO insiders buying or selling?

In the last 12 months, VBIO insiders reported 2 open-market purchases worth $28.4K and no sales. The latest trade was on Apr 15, 2026. See every trade.

What is the short interest in VBIO?

As of Oct 30, 2026, 230,766 VBIO shares were sold short, 1.0% of the shares outstanding, up 99.8% from the report before. At the average daily volume of 1.68M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.